Literature DB >> 30453435

[Estimation on the incidence and mortality of kidney cancer in China, in 2014].

S Z Liu1, L W Guo2, X Q Cao1, Q Chen1, S K Zhang1, M Zhang1, D Yu1, P L Quan1, X B Sun1, W Q Chen3.   

Abstract

Objective: To estimate the incidence and mortality of kidney cancer in China in 2014, based on the cancer registration data. Data was collected through the National Central Cancer Registry (NCCR).
Methods: All together, 449 cancer registries submitted required data on incidence and deaths of kidney cancer occurred in 2014, to the NCCR. After evaluation on the quality of data,339 registries were accepted for analysis and stratified by areas (urban/rural) and age groups. Combined with data from the National population in 2014, the nationwide incidence and mortality of kidney cancer were estimated. Data from the 2000 National census was used, and with Segi's population used for the rates of age-standardized incidence/mortality.
Results: The qualified 339 cancer registries covered a total population of 288 243 347, with 144 061 915 in urban and 144 181 432 in rural areas. The percentage of morphologically verified cases and cases with only available death certificates were 72.70% and 1.27%, respectively. The mortality to incidence ratio was 0.37. The estimates of new cases were around 68 300 in whole China, in 2014, with a crude incidence rate as 4.99/100 000 (95%CI: 4.95/100 000-5.03/100 000). The age-standardized incidence rates of kidney cancer, estimated by China standard population (ASR China) and world standard population (ASR world) were 3.43/100 000 (95%CI: 3.40/100 000-3.46/100 000) and 3.40/100 000 (95%CI: 3.37/100 000- 3.43/100 000), respectively. The cumulative incidence rate of kidney cancer was 0.40% in China. The crude and ASR China incidence rates for males appeared as 6.09/100 000 (6.03/100 000-6.15/100 000) and 4.32/100 000 (4.28/100 000-4.36/100 000), respectively, whereas those were 3.84/100 000 (3.79/100 000-3.89/100 000) and 2.54/100 000 (2.50/100 000-2.58/100 000) for females. The crude and ASR China incidence rates in urban areas appeared as 6.60/100 000 (95%CI: 6.54/100 000-6.66/100 000) and 4.25/100 000 (95%CI: 4.21/100 000-4.29/100 000), respectively, whereas those were 3.05/100 000 (95%CI: 3.01/100 000-3.09/100 000) and 2.29/100 000 (95%CI: 2.25/100 000-2.33/100 000) in rural areas. The estimates of kidney cancer deaths were around 25 600 in the country, in 2014, with a crude mortality rate of 1.87/100 000 (95%CI: 1.85/100 000-1.89/100 000). The ASR China and ASR world mortality rates appeared as 1.16/100 000 (95%CI: 1.14/100 000-1.18/100 000) and 1.16/100 000(95%CI: 1.14/100 000-1.18/100 000), respectively, with a cumulative mortality rate (0-74 years old) of 0.12%. The crude and ASR China mortality rates were 2.31/100 000 (95%CI: 2.27/100 000- 2.35/100 000) and 1.52/100 000 (95%CI: 1.50/100 000-1.54/100 000) for males, respectively, whereas those were 1.41/100 000 (95%CI: 1.38/100 000-1.44/100 000) and 0.81/100 000 (95%CI: 0.79/100 000- 0.83/100 000) for females. The crude and ASR China mortality rates were 2.49/100 000 (95%CI: 2.45/100 000-2.53/100 000) and 1.42/100 000 (95%CI: 1.40/100 000-1.44/100 000) in urban areas, respectively, whereas those were 1.12/100 000 (95%CI: 1.09/100 000-1.15/100 000) and 0.78/100 000 (95%CI: 0.76/100 000-0.80/100 000) in the rural areas. Conclusions: Both the incidence and mortality of kidney cancer seemed low, in China. However, the incidence of kidney cancer had greatly increased. Our findings suggested that prevention and control strategies for kidney cancer should be focused on males in the urban areas.

Entities:  

Keywords:  Incidence; Mortality; Neoplasms, kidney

Mesh:

Year:  2018        PMID: 30453435     DOI: 10.3760/cma.j.issn.0254-6450.2018.10.011

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  6 in total

1.  Effects of metabolic syndrome on renal function after radical nephrectomy in patients with renal cell carcinoma.

Authors:  Yong Zhang; Tingkun Wu; Jingjing Xie; Liqun Yan; Xiuli Guo; Weijia Xu; Liping Wang
Journal:  Int Urol Nephrol       Date:  2021-01-18       Impact factor: 2.370

2.  Expression of VEGF, CD73 and their relationship with clinical pathology, microvessel density, and prognosis in renal cell carcinoma.

Authors:  Xuefeng Mei; Jia Shu; Ruizhen Huang; Xin Chu; Ying Tian
Journal:  Transl Androl Urol       Date:  2020-06

3.  A Novel mRNA-miRNA Regulatory Sub-Network Associated With Prognosis of Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Tianyu Yang; Xiaofen Miao; Zhanxiang Bai; Jian Tu; Shanshan Shen; Hui Niu; Wei Xia; Juan Wang; Yongsheng Zhang
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

4.  Germline Mutation Landscape and Associated Clinical Characteristics in Chinese Patients With Renal Cell Carcinoma.

Authors:  Wen Kong; Tongtong Yang; Xiaodong Wen; Zhongyi Mu; Cheng Zhao; Sujun Han; Jing Tian; Xinhao Zhang; Tao Zhou; Yanrui Zhang; Feng Lou; Shanbo Cao; Huina Wang; Jin Zhang
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

Review 5.  Asian Conference on Tumor Ablation guidelines for renal cell carcinoma.

Authors:  Byung Kwan Park; Shu Huei Shen; Masashi Fujimori; Yi Wang
Journal:  Investig Clin Urol       Date:  2021-07

6.  A case report of the pancreatic and periampullary metastases of renal cell carcinoma, 17 years after surgery.

Authors:  Ruiling Lu; Ying Ying; Zhenhua Zhu; Hongping Wan; Guohua Li; Xu Shu; Wangdi Liao
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.